When will a Phase 2/3 trial show an aging-biology target improving a hard functional endpoint beyond molecular markers?
Chance it happens
67%Belief the predicted event happens at all — every “yes / by-a-date” outcome added together. “Other” is tracked as its own third slice.
Outcomes
Resolution criteria
A registered Phase 2 or 3 trial reports an improvement in a functional primary endpoint (strength, gait, event) — not just a molecular marker. Resolution horizon: 2032-12-31. Source: registry, publication.
Description
The catch this market is really asking about: today's aging drugs mostly move a molecular marker — a lab number like an epigenetic "aging clock", an inflammation reading (CRP, IL-6), or a count of senescent cells in a biopsy. Moving a number is easy and proves little on its own; a person can have a prettier blood panel and still be just as weak and frail. A functional endpoint is the opposite — something you can actually feel, or that changes a life. Examples: grip strength, walking (gait) speed, how far someone gets in a six-minute walk, a frailty index (a 0–1 score built from dozens of health deficits — the more deficits, the higher and worse the score), the rate of falls, or a hard clinical event (a fracture, a hospitalization, a death). These are what regulators and patients actually care about, and they are far harder to shift than a biomarker. An aging-biology target means the drug aims at a root mechanism of aging — clearing senescent cells (senolytics), mTOR/rapamycin, NAD+ boosting, partial reprogramming, and the like — not an ordinary single-disease drug that happens to help. So the whole thing in plain words: when will a real human trial (Phase 2 = does it work, and at what dose; Phase 3 = large confirmatory) of an anti-aging drug show it doesn't just prettify a lab number, but actually makes people measurably stronger, faster, or less frail — or prevents a hard event like a fracture or hospitalization? The bar is deliberately high: the improvement has to be the trial's declared primary functional endpoint, not a molecular marker that happened to move on the side. Resolution horizon: 2032.
Evidence & context
Trials, publications and reports our research found on this prognosis. Each links to the original source.
This appears to be a peer-reviewed perspective/review on appropriate clinical endpoints for geroscience trials, focusing on functional and health outcomes rather than molecular biomarkers. It bears on the prediction by indicating how the field defines meaningful Phase 2/3 success and suggesting the evidentiary bar for an aging-biology target to count as a resolution event.